- $1.05m
- -$1.02m
- 41
- 85
- 37
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.78 | ||
| Price to Tang. Book | 9.78 | ||
| Price to Free Cashflow | 1.04 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | -2.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 321.11% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Directors
- Louis Ignarro CHM (80)
- Stephen Snowdy CEO
- John Caloz CFO (69)
- Joel Caldwell IND (66)
- Jennifer Simpson IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 28th, 1985
- Public Since
- November 10th, 1986
- No. of Shareholders
- 180
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 495,092
- Address
- 11726 San Vicente Boulevard, Suite 650, LOS ANGELES, 90049
- Web
- https://www.ladrxcorp.com/
- Phone
- +1 3108265648
- Contact
- John Caloz
- Auditors
- Weinberg & Company
Upcoming Events for LADX
Q2 2024 LadRx Corp Earnings Release
LadRx Corp Annual Shareholders Meeting
Similar to LADX
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the LadRx share price?
As of Today at 19:13 UTC, shares in LadRx are trading at $2.12. This share price information is delayed by 15 minutes.
How has the LadRx share price performed this year?
Shares in LadRx last closed at $2.12 and the price had moved by -69.71% over the past 365 days. In terms of relative price strength the LadRx share price has underperformed the S&P500 Index by -73.28% over the past year.
What are the analyst and broker recommendations for LadRx?
The overall consensus recommendation for LadRx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the LadRx dividend yield?
LadRx does not currently pay a dividend.
Does LadRx pay a dividend?
LadRx does not currently pay a dividend.
When does LadRx next pay dividends?
LadRx does not currently pay a dividend.
How do I buy LadRx shares?
To buy shares in LadRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LadRx?
As of the previous close price of $2.12, shares in LadRx had a market capitalisation of $1.05m.
Where are LadRx shares listed?
Here are the trading details for LadRx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LADX
What kind of share is LadRx?
Based on an overall assessment of its quality, value and momentum LadRx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LadRx share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the LadRx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LadRx. Over the past six months, its share price has outperformed the S&P500 Index by +34.38%.
As of the last closing price of $2.12, shares in LadRx were trading -37.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LadRx PE Ratio?
The LadRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LadRx?
LadRx's management team is headed by:
- Louis Ignarro - CHM
- Stephen Snowdy - CEO
- John Caloz - CFO
- Joel Caldwell - IND
- Jennifer Simpson - IND